The Essential Tremor drugs in development market research report provides comprehensive information on the therapeutics under development for Essential Tremor, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Essential Tremor. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Essential Tremor - Drugs In Development, 2023

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Essential Tremor and features dormant and discontinued products.

GlobalData tracks 18 drugs in development for Essential Tremor by 15 companies/universities/institutes. The top development phase for Essential Tremor is phase ii with eight drugs in that stage. The Essential Tremor pipeline has 17 drugs in development by companies and one by universities/ institutes. Some of the companies in the Essential Tremor pipeline products market are: AfaSci, Jazz Pharmaceuticals and Neurocrine Biosciences.

The key targets in the Essential Tremor pipeline products market include Gamma-Aminobutyric Acid Type A Receptor Subunit (GABA(A) Receptor or GABR), Voltage Dependent T Type Calcium Channel, and Synaptosomal Associated Protein 25 (Synaptosomal Associated 25 kDa Protein or Super Protein or SNAP25).

The key mechanisms of action in the Essential Tremor pipeline product include Voltage Dependent T Type Calcium Channel Blocker with three drugs in Phase III. The Essential Tremor pipeline products include eight routes of administration with the top ROA being Oral and two key molecule types in the Essential Tremor pipeline products market including Small Molecule, and Protein.

Essential Tremor overview

Essential tremor, formerly known as benign essential tremor or familial tremor, stands as one of the most prevalent movement disorders. Defined by a tremor in hands and arms during action, it may also impact the head, voice, or lower limbs without additional neurological signs. Onset can occur at any age, with adolescence and middle age (between 40 and 50) being common. The tremor’s progression varies, from remaining mild to slowly worsening. While the exact cause is unknown, studies indicate that mild cerebellar degeneration accompanies essential tremor, affecting the brain’s movement coordination center. In 50-70% of cases, it is an inherited condition, often manifesting early in life as familial tremor.

For a complete picture of Essential Tremor’s pipeline drug market, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.